ID   ADRB2_FELCA             Reviewed;         418 AA.
AC   Q9TST5;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   10-FEB-2021, entry version 144.
DE   RecName: Full=Beta-2 adrenergic receptor;
DE   AltName: Full=Beta-2 adrenoreceptor;
DE            Short=Beta-2 adrenoceptor;
GN   Name=ADRB2;
OS   Felis catus (Cat) (Felis silvestris catus).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Laurasiatheria; Carnivora; Feliformia; Felidae; Felinae; Felis.
OX   NCBI_TaxID=9685;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Cully D.F., Tremml G., Zachwieja S.;
RT   "Felis domesticus beta adrenergic receptor subtype 2.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced
CC       activation of adenylate cyclase through the action of G proteins. The
CC       beta-2-adrenergic receptor binds epinephrine with an approximately 30-
CC       fold greater affinity than it does norepinephrine (By similarity).
CC       {ECO:0000250|UniProtKB:P07550}.
CC   -!- SUBUNIT: Binds SLC9A3R1 and GPRASP1. Interacts with ARRB1 and ARRB2.
CC       Interacts with SRC, USP20 and USP33. Interacts with VHL; the
CC       interaction, which is increased on hydroxylation of ADRB2,
CC       ubiquitinates ADRB2 leading to its degradation. Interacts with EGLN3;
CC       the interaction hydroxylates ADRB2 facilitating VHL-E3 ligase-mediated
CC       ubiquitination. Interacts (via PDZ-binding motif) with SNX27 (via PDZ
CC       domain); the interaction is required when endocytosed to prevent
CC       degradation in lysosomes and promote recycling to the plasma membrane.
CC       Interacts with CNIH4. Interacts with ARRDC3.
CC       {ECO:0000250|UniProtKB:P07550}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P07550};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:P07550}. Early
CC       endosome {ECO:0000250|UniProtKB:P07550}. Golgi apparatus
CC       {ECO:0000250|UniProtKB:P07550}. Note=Colocalizes with VHL at the cell
CC       membrane. Activated receptors are internalized into endosomes prior to
CC       their degradation in lysosomes. Activated receptors are also detected
CC       within the Golgi apparatus. {ECO:0000250|UniProtKB:P07550}.
CC   -!- PTM: Palmitoylated; may reduce accessibility of Ser-345 and Ser-346 by
CC       anchoring Cys-341 to the plasma membrane. Agonist stimulation promotes
CC       depalmitoylation and further allows Ser-345 and Ser-346 phosphorylation
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated by PKA and BARK upon agonist stimulation, which
CC       mediates homologous desensitization of the receptor. PKA-mediated
CC       phosphorylation seems to facilitate phosphorylation by BARK.
CC   -!- PTM: Phosphorylation of Tyr-141 is induced by insulin and leads to
CC       supersensitization of the receptor. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated. Agonist-induced ubiquitination leads to sort
CC       internalized receptors to the lysosomes for degradation.
CC       Deubiquitination by USP20 and USP33, leads to ADRB2 recycling and
CC       resensitization after prolonged agonist stimulation. USP20 and USP33
CC       are constitutively associated and are dissociated immediately after
CC       agonist stimulation. Ubiquitination by the VHL-E3 ligase complex is
CC       oxygen-dependent (By similarity). {ECO:0000250}.
CC   -!- PTM: Hydroxylation by EGLN3 occurs only under normoxia and increases
CC       the interaction with VHL and the subsequent ubiquitination and
CC       degradation of ADRB2. {ECO:0000250}.
CC   -!- PTM: Palmitoylated. Mainly palmitoylated at Cys-341. Palmitoylation may
CC       reduce accessibility of phosphorylation sites by anchoring the receptor
CC       to the plasma membrane. Agonist stimulation promotes depalmitoylation
CC       and further allows Ser-345 and Ser-346 phosphorylation. Also undergoes
CC       transient, ligand-induced palmitoylation at Cys-265 probably by ZDHHC9,
CC       ZDHHC14 and ZDHHC18 within the Golgi. Palmitoylation at Cys-265
CC       requires phosphorylation by PKA and receptor internalization and
CC       stabilizes the receptor. Could be depalmitoylated by LYPLA1 at the
CC       plasma membrane. {ECO:0000250|UniProtKB:P07550}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRB2 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF192345; AAF04304.1; -; Genomic_DNA.
DR   RefSeq; NP_001009247.1; NM_001009247.1.
DR   SMR; Q9TST5; -.
DR   STRING; 9685.ENSFCAP00000007370; -.
DR   Ensembl; ENSFCAT00000007956; ENSFCAP00000007370; ENSFCAG00000007954.
DR   GeneID; 493767; -.
DR   KEGG; fca:493767; -.
DR   CTD; 154; -.
DR   VGNC; VGNC:59658; ADRB2.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000159538; -.
DR   HOGENOM; CLU_009579_11_0_1; -.
DR   InParanoid; Q9TST5; -.
DR   OMA; CLREHKA; -.
DR   OrthoDB; 614199at2759; -.
DR   Proteomes; UP000011712; Chromosome A1.
DR   Bgee; ENSFCAG00000007954; Expressed in liver and 9 other tissues.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0043235; C:receptor complex; ISS:HGNC-UCL.
DR   GO; GO:0008179; F:adenylate cyclase binding; IEA:Ensembl.
DR   GO; GO:0001540; F:amyloid-beta binding; IEA:Ensembl.
DR   GO; GO:0004941; F:beta2-adrenergic receptor activity; ISS:HGNC-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0051380; F:norepinephrine binding; ISS:HGNC-UCL.
DR   GO; GO:0015459; F:potassium channel regulator activity; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:HGNC-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; ISS:HGNC-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0045453; P:bone resorption; IEA:Ensembl.
DR   GO; GO:0050873; P:brown fat cell differentiation; IEA:Ensembl.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IEA:Ensembl.
DR   GO; GO:0002032; P:desensitization of G protein-coupled receptor signaling pathway by arrestin; ISS:HGNC-UCL.
DR   GO; GO:0002024; P:diet induced thermogenesis; IEA:Ensembl.
DR   GO; GO:0031649; P:heat generation; IEA:Ensembl.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contraction; IBA:GO_Central.
DR   GO; GO:0002025; P:norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure; IBA:GO_Central.
DR   GO; GO:2000969; P:positive regulation of AMPA receptor activity; IEA:Ensembl.
DR   GO; GO:1901098; P:positive regulation of autophagosome maturation; ISS:GO_Central.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IEA:Ensembl.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; IEA:Ensembl.
DR   GO; GO:1904504; P:positive regulation of lipophagy; ISS:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:HGNC-UCL.
DR   GO; GO:0061885; P:positive regulation of mini excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; IEA:Ensembl.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISS:HGNC-UCL.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IEA:Ensembl.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR000332; ADRB2_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248:SF21; PTHR24248:SF21; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00562; ADRENRGCB2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   3: Inferred from homology;
KW   Cell membrane; Disulfide bond; Endosome; G-protein coupled receptor;
KW   Glycoprotein; Golgi apparatus; Hydroxylation; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..418
FT                   /note="Beta-2 adrenergic receptor"
FT                   /id="PRO_0000069129"
FT   TOPO_DOM        1..34
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        35..58
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        59..71
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        72..95
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        96..106
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        107..129
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        130..150
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        151..174
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        175..196
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        197..220
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        221..274
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        275..298
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        299..305
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        306..329
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        330..418
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          193..207
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          286..293
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          312..316
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   MOTIF           415..418
FT                   /note="PDZ-binding"
FT   BINDING         113
FT                   /note="Agonist or antagonist"
FT                   /evidence="ECO:0000250"
FT   BINDING         118
FT                   /note="Agonist or antagonist"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         141
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P07550"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07550"
FT   MOD_RES         262
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         345
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000250|UniProtKB:P07550"
FT   MOD_RES         346
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000250|UniProtKB:P07550"
FT   MOD_RES         355
FT                   /note="Phosphoserine; by BARK"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         387
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         400
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000250"
FT   LIPID           265
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P07550"
FT   LIPID           341
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P07550"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        106..191
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        184..190
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
SQ   SEQUENCE   418 AA;  46736 MW;  C0D32A6A2C72472B CRC64;
     MGQPGNRSVF LLAPNGSHAP DQDGTQERND AWVVGMGIVM SLIVLAIVFG NVLVITAIAR
     FERLQTVTNY FITSLACADL VMGLAVVPFG ASHILMKMWT FGNFWCEFWT SIDVLCVTAS
     IETLCVIAVD RYFAITSPFK YQSLLTKNKA RVVILMVWIV SGLTSFLPIQ MHWYRATHQE
     AINCYAKETC CDFFTNQAYA IASSIVSFYL PLVVMVFVYS RVFQVAQRQL QKIDKSEGRF
     HAQNLSQVEQ DGRSGHGHRR ASKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD
     NLIPKEVYIL LNWVGYVNSA FNPLIYCRSP DFRIAFQELL CLRRSSLKAY GNGYSNNSNS
     RTDYAGEHSG GPLGQEKDSE VLCEDPPGTE NLANRQGTVP NDSIDSQGQN GSTNDSLL
//
